Board Member
Castle Biosciences Inc (CSTL)Equibles does not estimate personal net worth.
Get an email with a short summary when Castle Biosciences Inc publishes a filing, an earnings call transcript or a press release.
Get CSTL alertsDerek Maetzold is recorded as Board Member at Castle Biosciences Inc (CSTL) since January 1, 2007 and CEO at Castle Biosciences Inc (CSTL). The newest filing on record that lists Derek Maetzold as CEO and Board Member at Castle Biosciences Inc (CSTL) is dated April 8, 2026. The proxy statement of Castle Biosciences Inc reports total compensation of $6,941,074 for Derek Maetzold in fiscal 2024, including a base salary of $715,572. Disclosed compensation is on record for 7 fiscal years. Derek Maetzold has spoken on 26 earnings calls and 2 other investor events across 1 company, most recently for Castle Biosciences Inc on September 15, 2026. Castle Biosciences Inc is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Castle Biosciences Inc includes Frank Stokes (CFO), Kristen M. Oelschlager (COO), Kimberlee Caple (Board Member) and 2 others.
“So maybe I'll talk about the business top line and you can cover specific financials. So Castle Bioscience is a molecular diagnostics company. We have a number of tests on the decisions physicians make, but also improving outcomes.”
“Our team across all areas at Castle did a phenomenal job in executing on our growth plans and pulling it through the business, including revenue on the top line in evidence development and clinical research.”
“I'll run through a slide presentation, and then we can field questions as we have time for. So I would encourage you to review the disclaimers and forelooking statements, both here and in our most recent filing.”
“We delivered strong first quarter results, building on our momentum from 2025. Thanks to the strong execution by the entire CASEL team, we delivered revenue of $83.7 million.”
“We closed out a strong fourth quarter and delivered an outstanding year in 2025, driven by continued momentum across our core revenue drivers, disciplined execution and the dedication of our employees.”
2007-01-01–present
Last confirmed April 8, 2026
Start not stated–present
Last confirmed April 8, 2026
Diagnostics & Research · Healthcare
CEO, Board Member
2007-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Castle Biosciences Inc (CSTL) | President and CEO | $715,572 | $6,941,074 |
| 2023 | Castle Biosciences Inc (CSTL) | President and CEO | $686,400 | $1,605,984 |
| 2022 | Castle Biosciences Inc (CSTL) | President and CEO | $660,000 | $7,552,577 |
| 2021 | Castle Biosciences Inc (CSTL) | President and CEO | $625,000 | $6,521,857 |
| 2020 | Castle Biosciences Inc (CSTL) | President and CEO | $550,000 | $5,344,639 |
| 2019 | Castle Biosciences Inc (CSTL) | President and Chief Executive Officer | $769,562 | $4,132,353 |
| 2018 | Castle Biosciences Inc (CSTL) | President and Chief Executive Officer | $409,500 | $790,758 |
